Prediction of Venous Thrombosis During chemotherapy-the PINPOINT Study

Inclusion Criteria: * Patients with a diagnosis of ovarian, lung, gastric or pancreatic cancer scheduled to undergo a course of chemotherapy who are undergoing adjuvant or neoadjuvant chemotherapy, or who are undergoing chemotherapy for relapsed disease or patients receiving targeted therapy in combination with chemotherapy * Patients who are over 18 years of age * Patients who are able to give full and informed written consent Exclusion Criteria: * Prior history of a documented VTE event within the last 5 years (excluding central line associated events whereby patients completed anticoagulation \> 3 months previously) * Any history of significant haemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 5 years * Familial bleeding diathesis * Known diagnosis of disseminated intravascular coagulation. * Surgery within 2 weeks of first baseline sample (with the exception of porth-a-cath implantation or biopsy) * Chemotherapy or immunotherapy 4 weeks before first baseline sample * Currently receiving long term anticoagulant therapy (Low Molecular Weight Heparin(LMWH), Direct Oral Anticoagulants(DOACs), Warfarin). Patients receiving aspirin, ticlopidine, clopidogrel or LMWH at a prophylactic dosage for a short period (ie post cancer surgery or during short hospital stay) will be included provided they have completed thromboprophylaxis therapy at the first blood sampling time point.